Clinical Trial Update: A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of IBI363 in combination with Bevacizumab or Furuitinib for advanced colorectal cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Furuitinib (Furuitinib)
• IBI363

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Advanced Malignancies | Phase 1 | Status: RECRUITING